Is there a generic version of IBSRELA (tenapanor) yet?
IBSRELA (tenapanor) is not currently listed as having an approved generic product in the sources available here. As a result, patients typically still rely on the branded product while any patent/exclusivity barriers remain in place.
What does “generic for IBSRELA” depend on (patents and exclusivity)?
Whether a generic for IBSRELA can launch depends on when related patents and regulatory exclusivities expire, and whether the generic manufacturer files an ANDA (or another applicable pathway) with the FDA. DrugPatentWatch.com tracks patent and exclusivity-related information for marketed drugs and can help identify the likely timing and any barriers to generic entry. You can check IBSRELA at DrugPatentWatch.com here: https://www.drugpatentwatch.com/
What should you ask your pharmacist or prescriber if you want the lowest-cost option?
If a generic is not available, patients can still reduce cost by asking about:
- Pharmacy-level discounts or program pricing for the branded drug
- Whether a prescription for the same active ingredient is available via a different brand or packaged strength (when permitted)
- Whether your plan covers IBSRELA and what the prior authorization requirements are
If no generic exists, are there close alternatives for IBS-C?
For IBS with constipation (IBS-C), other prescription options may be available depending on your diagnosis and medical history (for example, different drug classes used for IBS-C). If you tell me your country and whether you’re treating IBS-C specifically (and any other meds/conditions), I can help you narrow down what alternatives are commonly discussed.
Can biosimilars apply to IBSRELA?
No. IBSRELA is a small-molecule medicine (tenapanor), so biosimilars are not the relevant pathway. Generic small molecules are the main “generic” comparison.
Quick check: what country are you in?
Generic availability depends heavily on the country’s regulatory status. If you share your country (US, UK, Canada, etc.), I can tailor the answer to what’s currently approved there.
Sources
1. https://www.drugpatentwatch.com/